These findings suggest that alterations in neuroprotective (SIRT1, Nrf2) and inflammatory (NLRP3) pathways, along with disease duration, are key determinants of fatigue severity in PD patients, supporting their role as potential biomarkers for symptom burden. This evidence concerns the gene SIRT1 and Parkinson disease.